An Affibody molecule is a chain of 58 amino acids (~6.5 kDa) that contains a modified B domain of the staphylococcal protein A and can be obtained through chemical synthesis or produced in bacteria with the use of recombinant technology (1). Because of their small size and high chemical and thermal stability, these molecules are used as radiolabeled probes for the targeted detection and treatment of malignant tumors as discussed elsewhere (1-3).The epidermal growth factor receptor 2 (HER2) is considered to be an important Affibody target because it is believed to promote the development of the malignant phenotype, it plays a role in the development of resistance to anticancer drugs and radiation therapy, it is overexpressed in several different cancer tumor cells, and it often indicates a poor prognosis for the patient (4). Several radionuclide-labeled Affibodies and their derivatives, such as ZHER2:342, have been evaluated to detect tumors expressing HER2 in preclinical studies as discussed by Tolmachev (5). Earlier, a derivative of the ZHER2:342 Affibody, designated ABY-002, which has the radiometal chelator 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA) linked directly to the N-terminal valine of the molecule was constructed, radiolabeled with 111In or 68Ga, and evaluated for the imaging of malignant tumors that express HER2 (6). Although radiolabeled ABY-002 (both with 111In or 68Ga) could detect these tumors under in vivo conditions, the ZHER2:342 Affibody derivative exhibited a reduced affinity for HER2 (KD = 65 pM) compared to the parent Affibody (KD = 22 pM).From this study, it was concluded that the reduced affinity of ABY-002 for the receptor is probably due to a steric hindrance from the DOTA moiety, which is located very close to the HER2 binding site of the molecule. Tolmachev et al. decided to introduce a linker between the DOTA moiety and the HER2 binding sequence and evaluate whether this modification reduced or abolished the steric obstruction that may reduce the affinity of the Affibody for the receptor (7). The investigators placed an aliphatic linker (6-aminohexanoic acid) between DOTA and the valine on the N-terminal of ABY-002, labeled the modified Affibody (ABY-003) with 111In ([111In]-ABY-003), and evaluated the biodistribution and tumor detection properties of [111In]-ABY-003 in mice bearing HER2-expressing LS174T cell xenograft tumors (a human colon adenocarcinoma cell line showing a moderate expression level of HER2) or SKOV-3 cell xenograft tumors (a human ovarian carcinoma cell line showing a high expression level of HER2) (7).

100 Deals associated with [111In]-ABY-003

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Cancer	Preclinical	United States	National Center for Biotechnology Information	23 Aug 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis